OrbiMed Advisors LLC
601 Lexington Avenue
(at 53rd Street), 54th Floor
New York
New York
10022-4629
United States
Tel: 212-739-6400
Website: http://www.orbimed.com/
57 articles with OrbiMed Advisors LLC
-
San Francisco-based Terremoto Biosciences launched with $75 million in Series A financing from OrbiMed and Third Rock Ventures as it develops highly targeted, small-molecule medicines.
-
Sionna hit the ground with a pipeline of first-in-class small molecules designed to fully restore the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein in CF patients.
-
Money on the Move: February 9 – 15
2/16/2022
As the market seems to be taking a turn against biotech stock, more companies are opting for private funding instead of going public for the moment. And VC firms are happy to jump in. -
ImmPACT Bio provided an optimistic update on a Phase I clinical study evaluating its CD19-CD20 bi-specific Chimeric Antigen Receptor T-cell (CAR-T) therapy.
-
The funds will be used to advance the firm's precision oncology research efforts and pipeline, particularly those involving the creation of alteration-specific therapies.
-
Dr. Tal Zaks and Dr. Sheila Gujrathi Join OrbiMed
11/1/2021
OrbiMed is pleased to announce two new team additions who are among the global biotechnology industry’s most talented and capable professionals.
-
The proceeds will be used for the companies' growth, to help develop their platforms and advance their pipelines.
-
Several biopharma companies announced Series B financing rounds or additional investment raises. Here’s a look.
-
The combined company out of the Humacyte SPAC will be called Humacyte and is expected to trade shares of common stock and warrants on the Nasdaq Global Select Market.
-
The two companies announced their exclusive collaboration that will harness Kumquat’s small molecule immuno-oncology platform's capabilities to discover novel clinical candidates.
-
Through its OrbNet platform, Entos has already forged various partnerships with investors and leaders in the pharmaceuticals, materials, and chemicals industries.
-
German biotechnology firm LEUKOCARE, which has operations in Milford, Connecticut, has announced the closing of $17.5 million financing round from New York investment firm Petrichor Healthcare Capital Management.
-
Temasek has committed $200 million to launch The G2 Bio Companies which focuses on the development of potential next-generation gene therapies.
-
SpliSense, which focuses on cystic fibrosis and other genetic pulmonary diseases, closed on a $28.5 million Series B financing round. The company plans to use the money to advance its pipeline.
-
OrbiMed Raises $3.5 Billion Across Private Investment Funds
3/1/2021
OrbiMed, a leading life sciences investment firm, announced $3.5 billion in commitments for its latest private investment funds, including $1.5 billion for OrbiMed Private Investments VIII, $800 million for OrbiMed Asia Partners IV, and $1.2 billion for OrbiMed Royalty & Credit Opportunities III. Investors in these new funds include a broad range of medical institutions, university endowments, foundations, pension funds
-
VectivBio Closes $110 Million Crossover Financing to Advance Transformational Medicines for Rare Diseases
10/15/2020
VectivBio's investor syndicate expands to include Surveyor Capital (a Citadel company), Cormorant Capital and Eventide Asset Management
-
Prelude Therapeutics Announces Closing of $50M Series C Financing
8/24/2020
Prelude Therapeutics, a privately-held, clinical-stage precision oncology company, announced that it has completed a $50 million Series C financing round led by Prelude’s two existing institutional investors, including OrbiMed Advisors LLC, and a new investor, Fidelity Management & Research Company LLC.
-
Aspen Neuroscience Launches With $6.5 Million Seed Funding to Advance First-of-its-Kind Personalized Cell Therapy for Parkinson's Disease
12/12/2019
Led by Chief Executive Officer Howard Federoff, M.D., Ph.D., Former Vice Chancellor for Health Affairs and Chief Executive Officer of the University of California Irvine Health System
-
Repare Therapeutics Announces US$82.5 Million Series B Financing
9/4/2019
Repare Therapeutics, a precision oncology company targeting specific vulnerabilities of tumors in genetically defined patient populations, announced the completion of a US$82.5 million Series B financing.
-
OrbiMed Comments on Takeda Pharmaceutical Company Limited Proxy Ahead of 143rd Ordinary General Meeting of Shareholders 2019
6/19/2019
OrbiMed Advisors LLC has evaluated the proxy voting recommendations from both Institutional Shareholder Services Inc. and the management of Takeda Pharmaceutical Company Ltd. ahead of the 143rd Ordinary General Meeting of Shareholders that will take place on June 27, 2019, in Yokohama, Japan.